Stephen Sloan, MD
Clinical Cardiac Electrophysiology · Doylestown, PANPI 1932140621
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,175 of the $30,384 with a category attached, or 89.4%. Pfizer accounts for 83.0% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $17,721 and has fallen 99.2% since, to $142 in 2025.
Across 162 payments — averaging $187.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$25K
- E.r. Squibb & Sons, L.L.C.$3K
- Johnson & Johnson$345
- Amgen$277
- Merck$222
- Novartis$205
- plus $1K from 16 others
Across 21 payments — averaging $8176.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Terumo BCT, Inc.$158K
- Merck$13K
- Bayer$820
What the payments were for
- Speaking & faculty fees$27,17589%
- Food & beverage$3,17110%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $25,233 |
| E.r. Squibb & Sons, L.L.C. | 19 | $3,094 |
| Johnson & Johnson | 17 | $345 |
| Amgen | 14 | $277 |
| Merck | 11 | $222 |
| Novartis | 13 | $205 |
| Preventice Services, LLC | 1 | $132 |
| AstraZeneca | 9 | $132 |
| Boehringer Ingelheim | 5 | $105 |
| Sanofi-aventis U.S. LLC | 6 | $103 |
| Amarin Pharma, Inc. | 6 | $85 |
| Altathera Pharmaceuticals LLC | 1 | $85 |
| Novo Nordisk | 5 | $84 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $80 |
| Abbott | 1 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Medtronic | 2 | $33 |
| Boston Scientific | 1 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Bayer | 1 | $19 |
| Cardiva Medical, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,384 in reported general payments places this provider in the 65th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 745 | $881,182 |
| FarxigaDapagliflozin Propanediol | 173 | $142,676 |
| JardianceEmpagliflozin | 70 | $84,772 |
| EntrestoSacubitril/Valsartan | 64 | $83,763 |
| XareltoRivaroxaban | 44 | $62,880 |
| Repatha SureclickEvolocumab | 27 | $37,159 |
| Dofetilide | 63 | $10,670 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 39 | $10,543 |
| Metoprolol Succinate | 501 | $8,349 |
| DapagliflozinDapagliflozin Propanediol | 14 | $7,839 |
| PradaxaDabigatran Etexilate Mesylate | 25 | $6,217 |
| Atorvastatin Calcium | 419 | $6,212 |
| Rosuvastatin Calcium | 262 | $5,019 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 169 | $4,755 |
| Valsartan | 133 | $3,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25,233 | $881,182745 claims |
| AstraZenecaFarxiga | $132 | $142,676173 claims |
| Boehringer IngelheimJardiance, Pradaxa | $105 | $90,98995 claims |
| NovartisEntresto | $205 | $83,76364 claims |
| Johnson & JohnsonXarelto | $345 | $62,88044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Doylestown
- Philip WienerDoylestown$63K
- Seth WorleyLancaster$3.7M
- John ChenaridesPittsburgh$750K
- Fermin GarciaPhiladelphia$684K
- Ralph VerdinoPhiladelphia$682K
- Pugazhendhi VijayaramanWilkes Barre$594K
- Pasquale SantangeliPhiladelphia$581K
- Joshua SilversteinPittsburgh$557K
- Francis MarchlinskiPhiladelphia$469K
- Joshua CooperPhiladelphia$405K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.